Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disea...

Autor Bruera, Gemma, Ricevuto, Enrico
Vydáno v Front Oncol (2020)

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

Autor Bruera, Gemma, Ricevuto, Enrico
Vydáno v Pharmgenomics Pers Med (2020)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy

Autor Bruera, Gemma, Russo, Antonio, Galvano, Antonio, Rizzo, Sergio, Ricevuto, Enrico
Vydáno v Oncotarget (2016)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

Autor Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Vicentini, Roberto, Ficorella, Corrado, Ricevuto, Enrico
Vydáno 2013

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment...

Autor BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Vydáno 2013

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

Autor BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Vydáno 2014

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemothe...

Autor Bruera, Gemma, D'Andrilli, Antonio, Simmaco, Maurizio, Guadagni, Stefano, Rendina, Erino Angelo, Ricevuto, Enrico
Vydáno v Front Oncol (2020)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer

Autor Bruera, Gemma, Massacese, Silvia, Galvano, Antonio, Mas, Antonella Dal, Guadagni, Stefano, Calvisi, Giuseppe, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
Vydáno v Oncotarget (2018)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-...

Autor Bruera, Gemma, Pepe, Francesco, Malapelle, Umberto, Pisapia, Pasquale, Mas, Antonella Dal, Di Giacomo, Daniela, Calvisi, Giuseppe, Troncone, Giancarlo, Ricevuto, Enrico
Vydáno v Oncotarget (2018)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction...

Autor Bruera, Gemma, Massacese, Silvia, Pepe, Francesco, Malapelle, Umberto, Dal Mas, Antonella, Ciacco, Eugenio, Calvisi, Giuseppe, Troncone, Giancarlo, Simmaco, Maurizio, Ricevuto, Enrico
Vydáno v Ther Adv Med Oncol (2019)

Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line...

Autor Bruera, Gemma, Giuliani, Antonio, Romano, Lucia, Chiominto, Alessandro, Di Sibio, Alessandra, Mastropietro, Stefania, Cosenza, Pierluigi, Ricevuto, Enrico, Schietroma, Mario, Carlei, Francesco
Vydáno v BMC Cancer (2019)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

Autor Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Frébourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Alesse, Edoardo, Ficorella, Corrado, Ricevuto, Enrico
Vydáno 2013

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

Autor Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Manetta, Rosa, Vicentini, Roberto, Carducci, Sergio, Saltarelli, Patrizia, Iapadre, Nerio, Coletti, Gino, Ficorella, Corrado, Ricevuto, Enrico
Vydáno 2014

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II st...

Autor Bruera, Gemma, Santomaggio, Alessandra, Cannita, Katia, Baldi, Paola Lanfiuti, Tudini, Marianna, De Galitiis, Federica, Mancini, Maria, Marchetti, Paolo, Antonucci, Adelmo, Ficorella, Corrado, Ricevuto, Enrico
Vydáno 2010

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

Autor Bruera, Gemma, Massacese, Silvia, Candria, Stefania, Galvano, Antonio, Manetta, Rosa, Giordano, Aldo Victor, Carducci, Sergio, Di Sibio, Alessandra, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
Vydáno v Oncotarget (2018)

Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study

Autor Ricevuto, Enrico, Cocciolone, Valentina, Mancini, Maria, Cannita, Katia, Romano, Silvio, Bruera, Gemma, Pelliccione, Michela, Adinolfi, Maria Ilaria, Ciccozzi, Antonietta, Bafile, Alberto, Penco, Maria, Ficorella, Corrado
Vydáno v Oncologist (2015)

Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications

Autor Scumaci, Domenica, Tammè, Laura, Fiumara, Claudia Vincenza, Pappaianni, Giusi, Concolino, Antonio, Leone, Emanuela, Faniello, Maria Concetta, Quaresima, Barbara, Ricevuto, Enrico, Costanzo, Francesco Saverio, Cuda, Giovanni
Vydáno v PLoS One (2015)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting

Autor Cannita, Katia, Paradisi, Stefania, Cocciolone, Valentina, Bafile, Alberto, Rinaldi, Lucia, Irelli, Azzurra, Lanfiuti Baldi, Paola, Zugaro, Luigi, Manetta, Rosa, Alesse, Edoardo, Ricevuto, Enrico, Ficorella, Corrado
Vydáno v Cancer Med (2016)

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy...

Autor Guadagni, Stefano, Fiorentini, Giammaria, Mambrini, Andrea, Masedu, Francesco, Valenti, Marco, Mackay, Andrew Reay, Sarti, Donatella, Ricevuto, Enrico, Clementi, Marco, Catarci, Marco, Lazzarin, Gianni, Bruera, Gemma
Vydáno v Oncotarget (2019)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer

Autor Bruera, Gemma, Di Staso, Mario, Bonfili, Pierluigi, Galvano, Antonio, Manetta, Rosa, Coletti, Gino, Vicentini, Roberto, Guadagni, Stefano, Ficorella, Corrado, Di Cesare, Ernesto, Russo, Antonio, Ricevuto, Enrico
Vydáno v Oncotarget (2018)